Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 5/20 | 0.53 |
| ▸ | TLR4 | O00206 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ABL2 | P42684 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960004 | 1.00 | RXRA (0.58) | RXRAFBP1TLR4TLR2NFKB1 | |
| SCHEMBL9328746 | 1.00 | RXRA (0.58) | RXRAFBP1TLR4TLR2NFKB1 | |
| SCHEMBL1805981 | 0.85 | RXRA (0.54) | RXRAFBP1TLR4TLR2EGFR | |
| SCHEMBL1805984 | 0.85 | RXRA (0.54) | RXRAFBP1TLR4TLR2EGFR | |
| SCHEMBL13930333 | 0.78 | RXRA (0.59) | RXRAFBP1TLR4TLR2EGFR | |
| SCHEMBL8413165 | 0.77 | MAPT (0.62) | NFKB1MAPTLMNATRPA1NPC1 | |
| SCHEMBL104148 | 0.76 | HSP90AA1 (0.63) | RXRAFBP1TLR4TLR2MAPT | |
| SCHEMBL470811 | 0.76 | NFE2L2 (0.58) | RXRAFBP1TLR4TLR2NFE2L2 | |
| SCHEMBL798354 | 0.76 | RXRA (0.58) | RXRAFBP1TLR4TLR2MAPT | |
| SCHEMBL4723192 | 0.76 | NFE2L2 (0.58) | RXRAFBP1TLR4TLR2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041340-B | 6-aryl-benzofuran carbazole compounds and preparation and application thereof | 浙江大学 | 2020-12-18 | — | — | CN | claimed |
| CN-110041340-B | 6-aryl-benzofuran carbazole compounds and preparation and application thereof | 浙江大学 | 2020-12-18 | — | — | CN | disclosed |
| CN-110041340-B | 6-aryl-benzofuran carbazole compounds and preparation and application thereof | 浙江大学 | 2020-12-18 | — | — | CN | disclosed |
| EP-2982368-A1 | Small molecule compounds displacing focal adhesion core components | Universität Konstanz (DE) | 2016-02-10 | — | — | EP | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| WO-2011050270-A2 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050276-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | RXRA 598/4885FBP1 1046/4885TLR4 3904/4885 |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | RXRA 598/4885FBP1 1046/4885TLR4 3904/4885 |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | RXRA 4612/4885FBP1 609/4885TLR4 4209/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | RXRA 598/4885FBP1 1046/4885TLR4 3904/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | RXRA 598/4885FBP1 1046/4885TLR4 3904/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | RXRA 624/4885FBP1 1379/4885TLR4 3834/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | RXRA 625/4885FBP1 1132/4885TLR4 3768/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | RXRA 598/4885FBP1 1046/4885TLR4 3904/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | RXRA 4651/4885FBP1 670/4885TLR4 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.